AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 61 min read$ALNY

SUPRAN BRYAN sold $399K of ALNY

SUPRAN BRYAN (EVP, CLO and Secretary) sold 1,758 shares of ALNYLAM PHARMACEUTICALS, INC. (ALNY) at $226.88 ($0.40M total) on 2026-10-02.

Original reporting
SEC EDGAR · SUPRAN BRYAN
Published Oct 6, 2026, 8:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 8:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ALNY
Bearish
medium confidence
Mentioned
$ALNY
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALNYBearishLow
01

Why it matters

The disclosed sale provides fresh data on insider holdings but is modest in scale.

02

Market read

A small insider sell; limited immediate trading impact.

03

What to watch

Bryan's sale represents less than 0.5% of total shares outstanding, unlikely to move the stock materially.

Relevance 4/10Novelty 4/10Timing: after-hours filing

Background

ALNYLAM Pharmaceuticals filed a Form 4 reporting an insider transaction by its EVP, CLO and Secretary.

Company-level read

Ticker impact

$ALNYBearishMedium confidence
Context

Form 4 shows EVP/Chief Legal Officer Supran Bryan sold 1,758 shares for $398,855, reducing his stake to 12,807 shares.

Expected impact

potential modest pressure as the market prices in the insider sell

Evidence & confidence

The sale size is modest relative to the company's market cap, but the insider's role adds some weight.

Market effects

Sector

None significant for the biotech sector.

Regional

No broader regional effect.

Global

Limited to investors tracking insider activity.

Counterpoint

What could challenge this read

The sale could be routine portfolio rebalancing, not a negative signal.

Key entities

  • person
    Supran Bryan

    EVP, Chief Legal Officer and Secretary of ALNYLAM

  • company
    ALNYLAM Pharmaceuticals, Inc.

    Biotech firm developing RNA therapeutics

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ALNY insider trading history →

Related articles

NOV 3
$ALNYMed

Alnylam to Present Five-Year HELIOS-B Data and Expanding Evidence on the Benefits of RNAi-Powered TTR Silencing with AMVUTTRA® (vutrisiran) at AHA and ISA 2026

Alnylam will present five-year data from the HELIOS-B Phase 3 study of AMVUTTRA (vutrisiran) at AHA and ISA 2026, showing long-term benefits in treating transthyretin amyloidosis (ATTR). The study includes open-label extension data and post hoc analyses demonstrating preserved exercise capacity and cardiopulmonary performance. Additional real-world evidence and comparisons with other treatments will also be presented.

stocktitan.net2 min
NOV 2
$AZNMed

Earnings roundup: AstraZeneca’s cost cuts, Alnylam’s slump and Regeneron’s resilience

AstraZeneca (AZN) reiterated its $80B revenue target by 2030, announced a $1.5B cost-savings program, and shares rose 7%. Alnylam (ALNY) reported $1.13B Amvuttra revenue, but shares fell 20% due to concerns over Medicare reimbursement and insurer policies. Regeneron (REGN) saw shares rise 13% after reporting record sales for Dupixent, Eylea, and Libtayo, beating expectations.

finance.yahoo.com7 min
OCT 30
$ALNYHighAI 8/10

What Just Happened To Alnylam Stock?

Alnylam Pharmaceuticals (ALNY) stock dropped 25.1% on October 29, 2026, despite beating Q3 revenue estimates. Management expressed dissatisfaction with demand growth, lowering TTR product sales guidance. Product revenue grew 52% YoY, led by AMVUTTRA. The stock's decline was independent of sector and market trends.

finance.yahoo.com2 min
OCT 30
$ALNYHigh

Raymond James cuts Alnylam stock rating on Amvuttra uncertainty

Raymond James downgraded Alnylam Pharmaceuticals (ALNY) to Outperform from Strong Buy, lowering its price target to $315 from $420. The move follows Alnylam's Q3 2026 results, citing uncertainty around Amvuttra's near-term trends. The stock has dropped 22% in a week, trading near its 52-week low. Despite beating earnings estimates, concerns about softer guidance and commercial delays led to the downgrade. Stifel also downgraded ALNY to Hold, reducing its price target to $225.

investing.com2 min
OCT 29
$ALNYMed

Alnylam Pharmaceuticals Inc (ALNY) (Q3 2026) Earnings Call Highlights: TTR Franchise Surges

Alnylam Pharmaceuticals (ALNY) reported Q3 2026 earnings, highlighting a 59% surge in TTR franchise but noting challenges. AMVUTRA demand growth lagged, and Q4 headwinds are expected due to inventory, pricing, and 340B rule uncertainty. The company delayed 2027 guidance. Management discussed strategies to address demand growth hurdles and potential 340B impacts. Key events, including data releases and clinical development updates, were outlined.

finance.yahoo.com7 min